Petrovitch H, Vogt T M, Berge K G
John A. Burns School of Medicine, University of Hawaii.
Geriatrics. 1992 Mar;47(3):30-2, 35-8.
The Systolic Hypertension in the Elderly Program (SHEP) was the first clinical trial to demonstrate the efficacy of low-dose antihypertensive medication in preventing stroke in older individuals with isolated systolic hypertension (ISH). The trial was multicentered, double-blind, randomized, placebo-controlled and involved 4,736 men and women, black and white, age 60 and over with ISH. Results showed a highly significant 36% reduction in nonfatal plus fatal stroke over 5 years in the group treated with active medication (low-dose chlorthalidone was step one), compared with the placebo group. Nonfatal plus fatal coronary disease and cardiovascular disease were also significantly reduced with antihypertensive medication, by 27% and 32% respectively, and total mortality was lower by 13%.
老年收缩期高血压计划(SHEP)是首个证明低剂量抗高血压药物对预防单纯收缩期高血压(ISH)老年个体中风有效的临床试验。该试验为多中心、双盲、随机、安慰剂对照试验,纳入了4736名60岁及以上患有ISH的男性和女性,包括黑人和白人。结果显示,与安慰剂组相比,接受活性药物治疗(第一步为低剂量氯噻酮)的组在5年内非致命性加致命性中风显著降低了36%。抗高血压药物治疗还使非致命性加致命性冠心病和心血管疾病分别显著降低了27%和32%,总死亡率降低了13%。